The short version of Angiotensin IV analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
=== Purification === Due to the challenging chemical synthesis of the neurotoxin, most studies were conducted using a purified form. To investigate the effects of the α-bungarotoxin, the toxin has to be isolated from the venom of the elapid snake. The purification of the polypeptide is done via column chromatography. Firstly, the venom is dissolved in ammonium acetate buffer and then loaded on the CM-Sephadex column. The elution of the compound is done in two different steps by using an ammonium acetate buffer at a flow rate of 35 nl/h. The steps involve using two linear gradients of buffers while increasing the pH.
== References == Zerega, N. J. C. and T. J. Motley. 2001. Artocarpus (Moraceae) molecular phylogeny and the systematics and origins of breadfruit, Artocarpus altilis. Botanical Society of America Annual Meeting. Albuquerque, NM. August 12–16, 2001.
Aircraft de-icing: An 80 grams (2.8 oz) carbon nanotube aerogel could cover the wings of a jumbo jet. Aerogel heaters could operate continuously at low power, preventing ice from forming. Catalyst or catalyst carrier. Chemical adsorber: Silica aerogels have high surface area, porosity, and are ultrahydrophobic. They may be used to remove heavy metals, for example in wastewater treatment. Cosmic dust capture: NASA used aerogel to trap space dust particles aboard the Stardust spacecraft. The particles vaporize on impact with solids and pass through gases, but can be trapped in aerogels. NASA also used aerogel for thermal insulation for the Mars rovers. Drug delivery: Drugs can be adsorbed from supercritical CO2 with release rate controlled by varying the aerogel properties. Electrochemical double layer supercapacitors. Aerogels' high surface area allow capacitors that are .02-.05% the size of similarly rated electrolytic capacitors. Electromagnetic shielding Energy absorbers Fuel cells: platinum-on-carbon catalysts. Imaging devices, optics, and light guides. Impedance matchers for transducers, speakers and range finders. Inertial Confinement Fusion (ICF) and X-ray laser targets: In ICF, it is used as low-density target materials to create foam targets that aid in simulating the conditions necessary for fusion. Their low-density structure allows for precise control over the fusion fuel, facilitating efficient compression and heating by the laser energy. Introducing disorder into superfluid helium-3.
=== Policies === According to World Health Organization, policymakers can help tackle resistance by strengthening resistance-tracking and laboratory capacity and by regulating and promoting the appropriate use of medicines. Policymakers and industry can help tackle resistance by: fostering research and development of new tools and promoting cooperation and information sharing among all stakeholders.
Sources: en.wikipedia.org
The modes of action by which antimicrobial peptides kill microbes are varied, and may differ for different bacterial species. Some antimicrobial peptides kill both bacteria and fungi, e.g., psoriasin kills E. coli and several filamentous fungi. The cytoplasmic membrane is a frequent target, but peptides may also interfere with DNA and protein synthesis, protein folding, and cell wall synthesis. The initial contact between the peptide and the target organism is electrostatic, as most bacterial surfaces are anionic, or hydrophobic, such as in the antimicrobial peptide Piscidin. Their amino acid composition, amphipathicity, cationic charge and size allow them to attach to and insert into membrane bilayers to form pores by 'barrel-stave', 'carpet' or 'toroidal-pore' mechanisms. Alternately, they may penetrate into the cell to bind intracellular molecules which are crucial to cell living. Intracellular binding models includes inhibition of cell wall synthesis, alteration of the cytoplasmic membrane, activation of autolysin, inhibition of DNA, RNA, and protein synthesis, and inhibition of certain enzymes. In many cases, the exact mechanism of killing is not known. One emerging technique for the study of such mechanisms is dual polarisation interferometry. In contrast to many conventional antibiotics these peptides appear to be bactericidal instead of bacteriostatic. In general the antimicrobial activity of these peptides is determined by measuring the minimal inhibitory concentration (MIC), which is the lowest concentration of drug that inhibits bacterial growth.
Patella fossa: Shallow saucer-like concavity anteriorly, in which the lens rests, separated by Berger's space Ligamentum hyaloideocapsulare (Wieger's ligament): Circular thickening of vitreous 8–9mm in diameter, delineates the patella fossa Anterior hyaloid: Vitreous surface anterior to ora serrata. Continuous with and invests in the zonular fibres, and extends forward between the ciliary processes Vitreous base: Denser cortical area of vitreous. Firmly attached to the posterior 2mm of the pars plana, and the anterior 2–4mm of retina Posterior hyaloid surface: Closely applied to retinal internal limiting membrane. Firm attachment sites: Along blood vessels and at sites of retinal degeneration Space of Martegioni: A funnel shaped space overlying the optic disc with condensed edge Cloquet's canal: A 1–2 mm wide canal within the vitreous, from the space of Martegioni to the space of Berger, along an S-shaped course mainly below the horizontal. It is labelled "hyaloid canal" in the above diagram. Mittendorf's dot: A small circular opacity on the posterior lens capsule, which represents the site of attachment of the hyaloid artery before it subsequently regressed. Bergmeister's papilla: A tuft of fibrous tissue at the optic disc, which represents a remnant of the sheath associated with the hyaloid artery before it subsequently regressed. Internal structures of the vitreous
== Non-human infections == Streptococcus agalactiae was historically studied as a disease of cattle that harmed milk production, leading to its name "agalactiae" which means "absence of milk". Strains of bovine and human bacteria are generally interchangeable, with evidence of transmission from animals to humans and vice versa.
BoNT/FA received considerable attention under the name "BoNT/H", as it was mistakenly thought it could not be neutralized by any existing antitoxin. Botulinum toxins are closely related to tetanus toxin. The two are collectively known as Clostridium neurotoxins and the light chain is classified by MEROPS as family M27. Clostridium neurotoxins belong in the wider family of AB toxins, which also includes Anthrax toxin and Diphtheria toxin. Nonclassical types include BoNT/X (P0DPK1), which is toxic in mice and possibly in humans; a BoNT/J (A0A242DI27) found in cow Enterococcus; and a BoNT/Wo (A0A069CUU9) found in the rice-colonizing Weissella oryzae.
Dharmalingam, a Malaysian executed on 27 April 2022 at 6:00 am for trafficking of heroin in 2009 2022: Kalwant Singh Jogindar Singh and Norasharee Gous, a Malaysian and Singaporean respectively, who were both executed on 7 July 2022 for diamorphine trafficking in 2013 2022: Nazeri Lajim, a Singaporean executed on 22 July 2022 for importing 33.89g of diamorphine in 2012 2022: Abdul Rahim Shapiee and Ong Seow Ping, who were both Singaporeans, were hanged on 5 August 2022 for trafficking diamorphine in 2015 2023: Tangaraju Suppiah, a Singaporean hanged on 26 April 2023 for trafficking 1 kg of marijuana. 2023: Mohd Aziz bin Hussain, a Singaporean hanged on 26 July 2023 for trafficking 49.98g of diamorphine in 2017. 2023: Saridewi Djamani, a Singaporean woman hanged on 28 July 2023 for trafficking 30.72g of diamorphine in 2016. 2023: Mohamed Shalleh Abdul Latiff, a Singaporean and former delivery driver hanged on 3 August 2023 for trafficking 54.04g of diamorphine in 2019. 2024: 39-year-old Malaysian Pausi Jefridin and 53-year-old Singaporean Roslan Bakar, who were both hanged on 15 November 2024 for trafficking 96.07g of diamorphine in 2008. 2024: Rosman Abdullah, a 55-year-old Singaporean hanged on 22 November 2024 for trafficking 57.43g of diamorphine in 2009. 2025: Roshdi Abdullah Altway, a Singaporean, was hanged on 10 April 2025 for trafficking 78.77g of diamorphine. Roshdi was previously sentenced to hang in 1994 for the murder of a CNB inspector before he appealed and successfully reduced his death sentence to ten years' prison for manslaughter.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.